A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)

NCT00703586 Phase 1 COMPLETED

Hypothesis: Intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication, particularly in the gastrointestinal mucosa with resultant reduction in markers of immune activation and improved GI immune reconstitution.

Details

Lead sponsor	Rockefeller University
Phase	Phase 1
Status	COMPLETED
Enrolment	8
Start date	2007-09
Completion	2011-05

Conditions

• HIV Infections

Interventions

• Maraviroc

Primary outcomes

• MMC HIV RNA — 24 weeks

Countries

United States